Aclaris Therapeutics, Inc.

ACRS · Pharmaceutical Preparations · $809.6M
Cooling off
ACRS
$5.50
▲ +1.85%
09/18 O 5.41 H 5.54 L 5.36 C 5.50 ▲ +1.85%
Vol 4.7M RS 95
RS rating95
Now vs pivot (%)−16.67%
Tightening (ATR ratio)0.76×
Volume dry-up0.46×
Up/down volume, net0.08
From 52-week high17%
forming
Previous breakout trailed out ▲ +5.10% in Jun
Cooling off
Moving averages
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

The read

The base has run 3.6 weeks and fell 25% from its ceiling at its deepest. The pivot is $6.60, and the stock closed 16.7% below it. Its relative strength rating is 95.

Peers
Catalyst roadmap
  1. EarningstentativeLLY · competitorin 41d
    LLY reports
    Oct 29, 2026
  2. Earningstentativein 48d
    Quarterly earnings
    Nov 5, 2026
Flagged by the market sweep
GappedTape · 2026-09-15
+6.0%
Unusual volumeTape · 2026-09-15
3.7 sigma

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means.

In the news
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare ConferenceGlobeNewswire Inc. · 2026-09-03

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. Historical figures are backtests and are hypothetical.

What that means, in full
Aclaris Therapeutics, Inc. (ACRS) — The Tape